価格表

在庫・価格 : 2025年04月26日 14時16分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Anti-VEGF, Mouse-Mono(VG1)
データシート※最新のデータシートでない場合があります
NB100-664SS NOVノバス バイオロジカルス
Novus biologicals, LLC
0.025 mg ¥48,000
(未発注)
追加

在庫・価格 : 2025年04月26日 14時16分 現在

Anti-VEGF, Mouse-Mono(VG1)

  • 商品コード:NB100-664SS
  • メーカー:NOV
  • 包装:0.025mg
  • 価格: ¥48,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Turley H et al. Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J. Pathol. 1998 Nov;186(3):313-8
Turley H et al
1998/01/01
PubMed
2 Giatromanolaki A et al. DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. J. Pathol. 2003 Jun;200(2):222-8
Giatromanolaki A et al
2003/01/01
PubMed
3 Van der Auwera I et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin. Cancer Res. 2004 Dec;10(23):7965-71
Van der Auwera I et al
2004/01/01
Applications: PubMed
4 Adams J et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 2000 Jun;60(11):2898-905
Adams J et al
2000/01/01
Applications: PubMed
5 Couvelard A et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br. J. Cancer 2005 Jan;92(1):94-101
Couvelard A et al
2005/01/01
Applications: PubMed
6 Kakolyris S et al. Assessment of vascular maturation in non-small cell lung cancer using a novel basement membrane component, LH39: correlation with p53 and angiogenic factor expression. Cancer Res. 1999 Nov;59(21):5602-7
Kakolyris S et al
1999/01/01
Applications: PubMed
7 Koukourakis MI et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res. 2000 Jun;60(11):3088-95
Koukourakis MI et al
2000/01/01
Applications: PubMed
8 Giatromanolaki A et al. Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. Clin. Cancer Res. 2000 May;6(5):1917-21
Giatromanolaki A et al
2000/01/01
Applications: PubMed
9 Giatromanolaki A et al. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin. Cancer Res. 1998 Dec;4(12):3017-24
Giatromanolaki A et al
1998/01/01
Species: Human, Applications: IHC PubMed
10 O'Byrne KJ et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br. J. Cancer 2000 Apr;82(8):1427-32
O'Byrne KJ et al
2000/01/01
Species: Human, Applications: IHC-P, WB PubMed
11 Zhang HT et al. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br. J. Cancer 2000 Jul;83(1):63-8
Zhang HT et al
2000/01/01
Applications: PubMed
12 Kapsoritakis A et al. Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis 2003 Sep;18(5):418-22
Kapsoritakis A et al
2003/01/01
Applications: PubMed
13 Giatromanolaki A et al. Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. J. Clin. Pathol. 2003 Mar;56(3):209-13
Giatromanolaki A et al
2003/01/01
Applications: PubMed
14 Salgado R et al. Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. Br. J. Cancer 2002 Dec;87(12):1437-44
Salgado R et al
2002/01/01
Applications: PubMed
15 Hong DS et al. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin. Cancer Res. 2011 Oct;17(20):6582-91
Hong DS et al
2011/01/01
Applications: PubMed
16 Ptaszynska MM et al. Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells. Mol. Cancer Res. 2008 Mar;6(3):352-63
Ptaszynska MM et al
2008/01/01
Species: Human, Applications: WB PubMed
17 Giatromanolaki A et al. Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas. Eur J Surg Oncol 2003 Dec;29(10):879-83
Giatromanolaki A et al
2003/01/01
Applications: PubMed
18 Tam JC et al. A Chinese 2-herb formula (NF3) promotes hindlimb ischemia-induced neovascularization and wound healing of diabetic rats. J. Diabetes Complicat. ;28(4):436-47
Tam JC et al
Species: Rat, Applications: IHC-Fr PubMed
19 Fedorova LV et al. Peroxisome proliferator-activated receptor δ agonist, HPP593, prevents renal necrosis under chronic ischemia. PLoS ONE 2013;8(5):e64436
Fedorova LV et al
2013/01/01
Species: Rat, Applications: WB PubMed
20 Kunze D et al. Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. Int. J. Oncol. 2008 May;32(5):1049-56
Kunze D et al
2008/01/01
Species: Mouse, Applications: IHC-P PubMed
21 Johansen FF et al. Drug-induced hypothermia as beneficial treatment before and after cerebral ischemia. Pathobiology 2014;81(1):42-52
Johansen FF et al
2014/01/01
PubMed
22 Milanesi A et al. β-Cell regeneration mediated by human bone marrow mesenchymal stem cells. PLoS ONE 2012;7(8):e42177
Milanesi A et al
2012/01/01
Species: Mouse, Applications: IHC, ICC/IF PubMed
  • No.: 1
  • 文献情報:
    Turley H et al. Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J. Pathol. 1998 Nov;186(3):313-8
    Turley H et al
    1998/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Giatromanolaki A et al. DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. J. Pathol. 2003 Jun;200(2):222-8
    Giatromanolaki A et al
    2003/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Van der Auwera I et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin. Cancer Res. 2004 Dec;10(23):7965-71
    Van der Auwera I et al
    2004/01/01
  • 備考:
    Applications:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Adams J et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 2000 Jun;60(11):2898-905
    Adams J et al
    2000/01/01
  • 備考:
    Applications:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Couvelard A et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br. J. Cancer 2005 Jan;92(1):94-101
    Couvelard A et al
    2005/01/01
  • 備考:
    Applications:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Kakolyris S et al. Assessment of vascular maturation in non-small cell lung cancer using a novel basement membrane component, LH39: correlation with p53 and angiogenic factor expression. Cancer Res. 1999 Nov;59(21):5602-7
    Kakolyris S et al
    1999/01/01
  • 備考:
    Applications:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Koukourakis MI et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res. 2000 Jun;60(11):3088-95
    Koukourakis MI et al
    2000/01/01
  • 備考:
    Applications:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Giatromanolaki A et al. Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. Clin. Cancer Res. 2000 May;6(5):1917-21
    Giatromanolaki A et al
    2000/01/01
  • 備考:
    Applications:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Giatromanolaki A et al. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin. Cancer Res. 1998 Dec;4(12):3017-24
    Giatromanolaki A et al
    1998/01/01
  • 備考:
    Species: Human, Applications: IHC
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    O'Byrne KJ et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br. J. Cancer 2000 Apr;82(8):1427-32
    O'Byrne KJ et al
    2000/01/01
  • 備考:
    Species: Human, Applications: IHC-P, WB
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Zhang HT et al. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br. J. Cancer 2000 Jul;83(1):63-8
    Zhang HT et al
    2000/01/01
  • 備考:
    Applications:
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Kapsoritakis A et al. Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis 2003 Sep;18(5):418-22
    Kapsoritakis A et al
    2003/01/01
  • 備考:
    Applications:
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Giatromanolaki A et al. Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. J. Clin. Pathol. 2003 Mar;56(3):209-13
    Giatromanolaki A et al
    2003/01/01
  • 備考:
    Applications:
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Salgado R et al. Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. Br. J. Cancer 2002 Dec;87(12):1437-44
    Salgado R et al
    2002/01/01
  • 備考:
    Applications:
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Hong DS et al. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin. Cancer Res. 2011 Oct;17(20):6582-91
    Hong DS et al
    2011/01/01
  • 備考:
    Applications:
  • 参照:
    PubMed
  • No.: 16
  • 文献情報:
    Ptaszynska MM et al. Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells. Mol. Cancer Res. 2008 Mar;6(3):352-63
    Ptaszynska MM et al
    2008/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 17
  • 文献情報:
    Giatromanolaki A et al. Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas. Eur J Surg Oncol 2003 Dec;29(10):879-83
    Giatromanolaki A et al
    2003/01/01
  • 備考:
    Applications:
  • 参照:
    PubMed
  • No.: 18
  • 文献情報:
    Tam JC et al. A Chinese 2-herb formula (NF3) promotes hindlimb ischemia-induced neovascularization and wound healing of diabetic rats. J. Diabetes Complicat. ;28(4):436-47
    Tam JC et al
  • 備考:
    Species: Rat, Applications: IHC-Fr
  • 参照:
    PubMed
  • No.: 19
  • 文献情報:
    Fedorova LV et al. Peroxisome proliferator-activated receptor δ agonist, HPP593, prevents renal necrosis under chronic ischemia. PLoS ONE 2013;8(5):e64436
    Fedorova LV et al
    2013/01/01
  • 備考:
    Species: Rat, Applications: WB
  • 参照:
    PubMed
  • No.: 20
  • 文献情報:
    Kunze D et al. Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. Int. J. Oncol. 2008 May;32(5):1049-56
    Kunze D et al
    2008/01/01
  • 備考:
    Species: Mouse, Applications: IHC-P
  • 参照:
    PubMed
  • No.: 21
  • 文献情報:
    Johansen FF et al. Drug-induced hypothermia as beneficial treatment before and after cerebral ischemia. Pathobiology 2014;81(1):42-52
    Johansen FF et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 22
  • 文献情報:
    Milanesi A et al. β-Cell regeneration mediated by human bone marrow mesenchymal stem cells. PLoS ONE 2012;7(8):e42177
    Milanesi A et al
    2012/01/01
  • 備考:
    Species: Mouse, Applications: IHC, ICC/IF
  • 参照:
    PubMed